Shots:
- The US FDA has approved Simtriyo (centanafadine) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pts (≥6yrs.; ≥20kg), with availability expected later this year following scheduling by the US DEA
- Approval was supported by 4 P-III trials assessing Simtriyo vs PBO in children, adolescents, & adults with ADHD
- In two adult studies, both Simtriyo dose groups significantly improved AISRS total scores, with benefits emerging by Wk. 1 & sustained through 6wks. In paediatric & adolescent studies, high-dose Simtriyo significantly improved ADHD-RS-5 scores, with improvements seen as early as Wk. 1
Ref: Otsuka | Image: Otsuka | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
